Drug intelligence / Profile preview

thero2-01s22

Development stage: Phase 3
Lead developer: Institut de cancérologie Strasbourg Europe

Overview

Thero2-01s22 is an investigational drug under development for the treatment of HER2-positive breast cancer. Its mechanism of action is currently unknown, and it does not represent a novel mechanism. The drug is being developed by Institut de cancérologie Strasbourg Europe and has reached Phase 3 clinical trials for breast cancer, but as of now, it has not been approved in any country or for any indication. No adverse events have been reported in the available data[1][2][9].

Beyond the preview

Go deeper on thero2-01s22.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on thero2-01s22.

Explore the full profile